Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Addressing the inactivated poliovirus vaccine shortage.

Sutter RW, Zaffran M.

Lancet. 2019 May 16. pii: S0140-6736(19)30766-4. doi: 10.1016/S0140-6736(19)30766-4. [Epub ahead of print] No abstract available.

PMID:
31104831
2.

Facility-Associated Release of Polioviruses into Communities-Risks for the Posteradication Era.

Bandyopadhyay AS, Singh H, Fournier-Caruana J, Modlin JF, Wenger J, Partridge J, Sutter RW, Zaffran MJ.

Emerg Infect Dis. 2019 Jul;25(7):1363-1369. doi: 10.3201/eid2507.181703. Epub 2019 Jul 17.

3.

Inactivated Poliovirus Vaccine Supply Shortage: Is There Light at the End of the Tunnel?

Sutter RW, Cochi SL.

J Infect Dis. 2019 Apr 8. pii: jiy739. doi: 10.1093/infdis/jiy739. [Epub ahead of print] No abstract available.

PMID:
30958545
4.

Rapid Disappearance of Poliovirus Type 2 Immunity in Young Children Following Withdrawal of Oral Poliovirus Type 2 Containing Vaccine in Vietnam.

Huyen DTT, Mach O, Trung NT, Thai PQ, Thang HV, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW, Anh DD.

J Infect Dis. 2019 Mar 14. pii: jiz124. doi: 10.1093/infdis/jiz124. [Epub ahead of print]

PMID:
30869149
5.

Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.

Gamage D, Mach O, Ginige S, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW.

J Infect Dis. 2019 May 24;219(12):1887-1892. doi: 10.1093/infdis/jiz026.

PMID:
30649505
6.

Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria.

Verma H, Iliyasu Z, Craig KT, Molodecky NA, Urua U, Jibir BW, Gwarzo GD, Gajida AU, McDonald S, Weldon WC, Oberste MS, Braka F, Mkanda P, Sutter RW.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S103-S109. doi: 10.1093/cid/ciy637.

PMID:
30376090
7.

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?

Resik S, Tejeda A, Mach O, Fonseca M, Diaz M, Alemany N, Heng Hung L, Aleman Y, Mesa I, Garcia G, Sutter RW.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S51-S56. doi: 10.1093/cid/ciy604.

8.

Update on Vaccine-Derived Polioviruses - Worldwide, January 2017-June 2018.

Jorba J, Diop OM, Iber J, Henderson E, Zhao K, Sutter RW, Wassilak SGF, Burns CC.

MMWR Morb Mortal Wkly Rep. 2018 Oct 26;67(42):1189-1194. doi: 10.15585/mmwr.mm6742a5.

9.

Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014-2017.

Grassly NC, Wadood MZ, Safdar RM, Mahamud AS, Sutter RW.

Emerg Infect Dis. 2018 Nov;24(11):2113-2115. doi: 10.3201/eid2411.180050. Epub 2018 Nov 17.

10.

Progress Toward Poliovirus Containment Implementation - Worldwide, 2017-2018.

Fournier-Caruana J, Previsani N, Singh H, Boualam L, Swan J, Llewellyn A, Sutter RW, Zaffran M; MEng.

MMWR Morb Mortal Wkly Rep. 2018 Sep 7;67(35):992-995. doi: 10.15585/mmwr.mm6735a5.

11.

Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.

Blake IM, Pons-Salort M, Molodecky NA, Diop OM, Chenoweth P, Bandyopadhyay AS, Zaffran M, Sutter RW, Grassly NC.

N Engl J Med. 2018 Aug 30;379(9):834-845. doi: 10.1056/NEJMoa1716677.

12.

Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine.

Gamage D, Mach O, Palihawadana P, Zhang Y, Weldon WC, Oberste MS, Gunasena S, Sutter RW.

J Infect Dis. 2018 Nov 5;218(12):1876-1882. doi: 10.1093/infdis/jiy389.

PMID:
29982532
13.

Cuba's Scientific Contributions to Global Polio Eradication.

Resik S, Mach O, Tejeda A, Galindo MA, Sutter RW.

MEDICC Rev. 2018 Apr;20(2):40-42.

14.

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar.

Razafindratsimandresy R, Mach O, Heraud JM, Bernardson B, Weldon WC, Oberste MS, Sutter RW.

Heliyon. 2018 Mar 7;4(3):e00563. doi: 10.1016/j.heliyon.2018.e00563. eCollection 2018 Mar.

15.

Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017.

Hussain I, Mach O, Hamid NA, Bhatti ZS, Moore DD, Oberste MS, Khan S, Khan H, Weldon WC, Sutter RW, Bhutta ZA, Soofi SB.

Vaccine. 2018 Apr 5;36(15):1921-1924. doi: 10.1016/j.vaccine.2018.02.055. Epub 2018 Mar 3.

16.

Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.

Saleem AF, Yousafzai MT, Mach O, Khan A, Quadri F, Weldon WC, Oberste MS, Zaidi SS, Alam MM, Sutter RW, Zaidi AKM.

Vaccine. 2018 Mar 20;36(13):1766-1771. doi: 10.1016/j.vaccine.2018.02.051. Epub 2018 Feb 21.

17.

Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa.

Guindo O, Mach O, Doumbia S, Ekra DK, Beavogui AH, Weldon WC, Oberste MS, Sutter RW.

Vaccine. 2018 Feb 14;36(8):1027-1031. doi: 10.1016/j.vaccine.2018.01.022. Epub 2018 Jan 19.

PMID:
29358054
18.

Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan.

Yousafzai MT, Saleem AF, Mach O, Baig A, Sutter RW, Zaidi AKM.

Heliyon. 2017 Sep 18;3(8):e00395. doi: 10.1016/j.heliyon.2017.e00395. eCollection 2017 Aug.

19.

Unraveling the Mucosal Immunity of Inactivated Poliovirus Vaccine.

Sutter RW.

J Infect Dis. 2018 Jan 17;217(3):344-346. doi: 10.1093/infdis/jix557. No abstract available.

PMID:
29304197
20.

Global Polio Eradication - Way Ahead.

Bahl S, Bhatnagar P, Sutter RW, Roesel S, Zaffran M.

Indian J Pediatr. 2018 Feb;85(2):124-131. doi: 10.1007/s12098-017-2586-8. Epub 2018 Jan 5. Review.

21.

Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan.

Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Steven Oberste M, Zaidi SS, Alam MM, Quadri F, Sutter RW, Zaidi AKM.

J Infect Dis. 2018 Jan 17;217(3):443-450. doi: 10.1093/infdis/jix577.

PMID:
29126173
22.

Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.

Jorba J, Diop OM, Iber J, Henderson E, Sutter RW, Wassilak SGF, Burns CC.

MMWR Morb Mortal Wkly Rep. 2017 Nov 3;66(43):1185-1191. doi: 10.15585/mmwr.mm6643a6.

23.

Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.

Macklin G, Liao Y, Takane M, Dooling K, Gilmour S, Mach O, Kew OM, Sutter RW; iVDPV Working Group.

Front Immunol. 2017 Sep 25;8:1103. doi: 10.3389/fimmu.2017.01103. eCollection 2017.

24.

Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.

Aghamohammadi A, Abolhassani H, Kutukculer N, Wassilak SG, Pallansch MA, Kluglein S, Quinn J, Sutter RW, Wang X, Sanal O, Latysheva T, Ikinciogullari A, Bernatowska E, Tuzankina IA, Costa-Carvalho BT, Franco JL, Somech R, Karakoc-Aydiner E, Singh S, Bezrodnik L, Espinosa-Rosales FJ, Shcherbina A, Lau YL, Nonoyama S, Modell F, Modell V; JMF Centers Network Investigators and Study Collaborators, Barbouche MR, McKinlay MA.

Front Immunol. 2017 Jun 13;8:685. doi: 10.3389/fimmu.2017.00685. eCollection 2017.

25.

Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria.

Gofama MM, Verma H, Abdullahi H, Molodecky NA, Craig KT, Urua UA, Garba MA, Alhaji MA, Weldon WC, Oberste MS, Braka F, Muhammad AJG, Sutter RW.

PLoS One. 2017 Sep 26;12(9):e0185284. doi: 10.1371/journal.pone.0185284. eCollection 2017.

26.

Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization.

Okayasu H, Sein C, Chang Blanc D, Gonzalez AR, Zehrung D, Jarrahian C, Macklin G, Sutter RW.

J Infect Dis. 2017 Jul 1;216(suppl_1):S161-S167. doi: 10.1093/infdis/jix038.

27.

Seroprevalence of Anti-polio Antibodies in Children From Polio High-risk Areas of Pakistan: A Cross-Sectional Survey 2015-2016.

Hussain I, Mach O, Habib A, Bhatti Z, Suhag Z, Oberste MS, Weldon WC, Sutter RW, Soofi SB, Bhutta ZA.

Pediatr Infect Dis J. 2017 Sep;36(9):e230-e236. doi: 10.1097/INF.0000000000001622.

PMID:
28806355
28.

High population immunity reduces poliovirus community transmission.

Garon J, Sutter RW, Orenstein W.

Lancet Infect Dis. 2017 Oct;17(10):1009-1011. doi: 10.1016/S1473-3099(17)30417-6. Epub 2017 Jul 7. No abstract available.

29.

Progress Toward Containment of Poliovirus Type 2 - Worldwide, 2017.

Previsani N, Singh H, St Pierre J, Boualam L, Fournier-Caruana J, Sutter RW, Zaffran M; MEng.

MMWR Morb Mortal Wkly Rep. 2017 Jun 23;66(24):649-652. doi: 10.15585/mmwr.mm6624a5.

30.

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.

Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, Sutter RW, Zaidi AKM.

Vaccine. 2017 May 31;35(24):3209-3214. doi: 10.1016/j.vaccine.2017.04.075. Epub 2017 May 4.

31.

Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.

Anand A, Molodecky NA, Pallansch MA, Sutter RW.

Vaccine. 2017 May 19;35(22):2993-2998. doi: 10.1016/j.vaccine.2017.03.008. Epub 2017 Apr 20. Review.

PMID:
28434691
32.

Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived.

Sutter RW, Okayasu H, Kieny MP.

Clin Infect Dis. 2017 May 15;64(10):1326-1327. doi: 10.1093/cid/cix116. No abstract available.

PMID:
28200099
33.

Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial.

Resik S, Tejeda A, Diaz M, Okayasu H, Sein C, Molodecky NA, Fonseca M, Alemany N, Garcia G, Hung LH, Martinez Y, Sutter RW.

J Infect Dis. 2017 Jan 15;215(2):175-182. doi: 10.1093/infdis/jiw492.

PMID:
28073858
34.

Completing Polio Eradication: The Case for Antiviral Drugs.

Sutter RW, Modlin JF, Zaffran M.

J Infect Dis. 2017 Feb 1;215(3):333-334. doi: 10.1093/infdis/jiw547. No abstract available.

PMID:
27932609
35.

Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014-April 2016.

Shirreff G, Wadood MZ, Vaz RG, Sutter RW, Grassly NC.

Emerg Infect Dis. 2017 Feb;23(2):258-263. doi: 10.3201/eid2302.161210. Epub 2017 Feb 15.

36.

Development of inactivated poliovirus vaccine from Sabin strains: A progress report.

Okayasu H, Sein C, Hamidi A, Bakker WA, Sutter RW.

Biologicals. 2016 Nov;44(6):581-587. doi: 10.1016/j.biologicals.2016.08.005. Epub 2016 Oct 5. Review.

PMID:
27720268
37.

Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria.

Iliyasu Z, Verma H, Craig KT, Nwaze E, Ahmad-Shehu A, Jibir BW, Gwarzo GD, Gajida AU, Weldon WC, Steven Oberste M, Takane M, Mkanda P, Muhammad AJG, Sutter RW.

Vaccine. 2016 Sep 30;34(42):5125-5131. doi: 10.1016/j.vaccine.2016.08.058. Epub 2016 Aug 31.

38.

Update on Vaccine-Derived Polioviruses - Worldwide, January 2015-May 2016.

Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC.

MMWR Morb Mortal Wkly Rep. 2016 Aug 5;65(30):763-9. doi: 10.15585/mmwr.mm6530a3.

39.

Role of Serial Polio Seroprevalence Studies in Guiding Implementation of the Polio Eradication Initiative in Kano, Nigeria: 2011-2014.

Craig KT, Verma H, Iliyasu Z, Mkanda P, Touray K, Johnson T, Walla A, Banda R, Tegegne SG, Yehualashet YG, Abba B, Ahmad-Shehu A, Takane M, Sutter RW, Nsubuga P, Muhammad AJ, Vaz RG.

J Infect Dis. 2016 May 1;213 Suppl 3:S124-30. doi: 10.1093/infdis/jiv774. Epub 2016 Feb 9.

40.

Polio vaccine hesitancy in the networks and neighborhoods of Malegaon, India.

Onnela JP, Landon BE, Kahn AL, Ahmed D, Verma H, O'Malley AJ, Bahl S, Sutter RW, Christakis NA.

Soc Sci Med. 2016 Mar;153:99-106. doi: 10.1016/j.socscimed.2016.01.024. Epub 2016 Feb 4.

PMID:
26889952
41.

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.

Dey A, Molodecky NA, Verma H, Sharma P, Yang JS, Saletti G, Ahmad M, Bahl SK, Wierzba TF, Nandy RK, Deshpande JM, Sutter RW, Czerkinsky C.

PLoS One. 2016 Jan 5;11(1):e0146010. doi: 10.1371/journal.pone.0146010. eCollection 2016.

42.

Renaissance of an "old" vaccine.

Sutter RW, Kew OM.

Lancet Infect Dis. 2016 Mar;16(3):268-70. doi: 10.1016/S1473-3099(15)00526-5. Epub 2015 Dec 21. No abstract available.

PMID:
26719059
43.

Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.

Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB.

Lancet. 2015 Dec 12;386(10011):2413-21. doi: 10.1016/S0140-6736(15)00237-8. Epub 2015 Sep 18. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.

PMID:
26388534
44.

Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity.

Resik S, Tejeda A, Mach O, Sein C, Molodecky N, Jarrahian C, Saganic L, Zehrung D, Fonseca M, Diaz M, Alemany N, Garcia G, Hung LH, Martinez Y, Sutter RW.

Vaccine. 2015 Oct 26;33(43):5873-5877. doi: 10.1016/j.vaccine.2015.06.071. Epub 2015 Jul 17.

PMID:
26192350
45.

Achieving high seroprevalence against polioviruses in Sri Lanka--results from a serological survey, 2014.

Gamage D, Palihawadana P, Mach O, Weldon WC, Oberste SM, Sutter RW.

J Epidemiol Glob Health. 2015 Dec;5(4 Suppl 1):S67-71. doi: 10.1016/j.jegh.2015.06.004. Epub 2015 Jul 9.

46.

Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.

Mir F, Quadri F, Mach O, Ahmed I, Bhatti Z, Khan A, Rehman NU, Durry E, Salama M, Oberste SM, Weldon WC, Sutter RW, Zaidi AK.

Lancet Infect Dis. 2015 Aug;15(8):889-97. doi: 10.1016/S1473-3099(15)00093-6. Epub 2015 Jun 17.

47.

Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.

Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):640-6.

48.

Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.

Saleem AF, Mach O, Quadri F, Khan A, Bhatti Z, Rehman NU, Zaidi S, Weldon WC, Oberste SM, Salama M, Sutter RW, Zaidi AK.

Vaccine. 2015 Jun 4;33(24):2757-63. doi: 10.1016/j.vaccine.2015.04.055. Epub 2015 Apr 24.

49.

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies.

Resik S, Tejeda A, Fonseca M, Sein C, Hung LH, Martinez Y, Diaz M, Okayasu H, Sutter RW.

Trials Vaccinol. 2015;4:71-74.

50.

Zinc supplementation fails to increase the immunogenicity of oral poliovirus vaccine: a randomized controlled trial.

Habib MA, Soofi S, Sheraz A, Bhatti ZS, Okayasu H, Zaidi SZ, Molodecky NA, Pallansch MA, Sutter RW, Bhutta ZA.

Vaccine. 2015 Feb 4;33(6):819-25. doi: 10.1016/j.vaccine.2014.12.001. Epub 2014 Dec 11.

PMID:
25500307

Supplemental Content

Loading ...
Support Center